{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:59:21Z","timestamp":1793411961509,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ropeginterferon alfa-2b is increasingly used as a long-acting interferon therapy for polycythemia vera (PV), providing hematologic and molecular benefits. However, clinical studies have implemented different dose-escalation strategies, and their impact on outcomes has not been systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase, and the Cochrane Library (September 24, 2025) identified studies reporting clinical outcomes of ropeginterferon in PV. Nine studies met eligibility criteria. Two reviewers independently extracted data, and meta-analyses were conducted using random-effects models. Subgroup analyses compared slow dose-up (SDU) and rapid dose-up (RDU) regimens at 1-, 2-, and 3-year follow-up when available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The pooled 1-year complete hematologic response (CHR) rate was 0.59 (95% CI, 0.47\u20130.71). RDU regimens yielded significantly higher CHR than SDU at both 1 year (0.67 vs. 0.41;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and 2 years (0.75 vs. 0.63;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038). Molecular response (MR) also favored RDU at 1 year (0.59 vs. 0.36;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with differences diminishing at 2 years. The pooled 1-year reduction in JAK2 V617F allele burden was \u2212\u200922.2% (95% CI, \u2212\u200934.2% to \u2212\u200910.2%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Safety outcomes were favorable, with low rates of thrombosis (4%), serious adverse events (5%), and treatment discontinuation (7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ropeginterferon alfa-2b provides meaningful hematologic and molecular responses with an acceptable safety profile in PV. Rapid dose-escalation facilitates earlier CHR and MR without increasing toxicity, suggesting titration speed as an important determinant of early treatment optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15939-x","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:16:11Z","timestamp":1775913371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ropeginterferon dose-escalation strategies in polycythemia vera: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Seug Yun","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namsu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Ho","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"15939_CR1","doi-asserted-by":"crossref","unstructured":"Kralovics R, Passamonti F, Buser Andreas S, Teo S-S, Tiedt R, Passweg Jakob R et al. A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. N Engl J Med. 2025;352(17):1779\u201390.","DOI":"10.1056\/NEJMoa051113"},{"issue":"0","key":"15939_CR2","first-page":"S83","volume":"58","author":"SY Yoon","year":"2023","unstructured":"Yoon SY, Won J-H. Novel therapeutic strategies for essential thrombocythemia\/polycythemia vera. BR. 2023;58(0):S83\u20139.","journal-title":"BR"},{"issue":"6","key":"15939_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3904\/kjim.2023.333","volume":"38","author":"SY Yoon","year":"2023","unstructured":"Yoon SY, Kim SY. Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms. Korean J Intern Med. 2023;38(6):810\u20137.","journal-title":"Korean J Intern Med"},{"issue":"3","key":"15939_CR4","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013208.","journal-title":"Lancet Haematol"},{"issue":"3","key":"15939_CR5","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175\u201384.","journal-title":"Lancet Haematol"},{"issue":"3","key":"15939_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ijc.35411","volume":"157","author":"SY Yoon","year":"2025","unstructured":"Yoon SY, Yoon S-S, Yang D-H, Lee G-W, Sohn SK, Shin H-J, et al. Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study. Int J Cancer. 2025;157(3):526\u201333.","journal-title":"Int J Cancer"},{"issue":"7","key":"15939_CR7","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00277-024-05809-6","volume":"103","author":"F Palandri","year":"2024","unstructured":"Palandri F, Branzanti F, Venturi M, Dedola A, Fontana G, Loffredo M, et al. Real-life use of ropeg-interferon \u03b12b in polycythemia vera: patient selection and clinical outcomes. Ann Hematol. 2024;103(7):2347\u201354.","journal-title":"Ann Hematol"},{"issue":"1\u20132","key":"15939_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14740\/jh1245","volume":"13","author":"SS Suo","year":"2024","unstructured":"Suo SS, Fu RF, Qin A, Shao ZH, Bai J, Chen SN, et al. Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment. J Hematol. 2024;13(1\u20132):12\u201322.","journal-title":"J Hematol"},{"issue":"12","key":"15939_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.clml.2025.06.011","volume":"25","author":"YS Chang","year":"2025","unstructured":"Chang YS, Liu CY, Chen YW, Huang SH, Lin HY, Lin CC, et al. Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study. Clin Lymphoma Myeloma Leuk. 2025;25(12):885\u201396.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"15939_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022;116(2):215\u201327.","journal-title":"Int J Hematol"},{"issue":"7","key":"15939_CR11","doi-asserted-by":"publisher","first-page":"e7166","DOI":"10.1002\/cam4.7166","volume":"13","author":"CC Chen","year":"2024","unstructured":"Chen CC, Kuo MC, Wang YH, Pei SN, Huang ML, Chen CC, et al. Treatment outcome and germline predictive factors of ropeginterferon alpha-2b in myeloproliferative neoplasm patients. Cancer Med. 2024;13(7):e7166.","journal-title":"Cancer Med"},{"issue":"15","key":"15939_CR12","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762\u20139.","journal-title":"Blood"},{"issue":"1","key":"15939_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333.","journal-title":"N Engl J Med"},{"issue":"5","key":"15939_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36(5):1408\u201311.","journal-title":"Leukemia"},{"issue":"1","key":"15939_CR15","first-page":"335","volume":"104","author":"A Yacoub","year":"2025","unstructured":"Yacoub A, Abu-Zeinah G, Qin A, Tashi T, Da\u2019na W, Shih WJ, et al. PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera. Ann Hematol. 2025;104(1):335\u201345.","journal-title":"Ann Hematol"},{"issue":"11","key":"15939_CR16","doi-asserted-by":"publisher","first-page":"e862","DOI":"10.1016\/S2352-3026(25)00264-9","volume":"12","author":"R Mesa","year":"2025","unstructured":"Mesa R, Gill H, Zhang L, Jin J, Kirito K, Komatsu N, et al. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol. 2025;12(11):e862\u201375.","journal-title":"Lancet Haematol"},{"issue":"6","key":"15939_CR17","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","volume":"35","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, et al. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia. 2021;35(6):1643\u201360.","journal-title":"Leukemia"},{"key":"15939_CR18","doi-asserted-by":"crossref","unstructured":"Nada EA, Elfagieh MA, Abdelsalam F, Elrashedy AA, Idres FA, Shata A et al. Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis. Ann Hematol. 2025;104(12):6131\u2013452025","DOI":"10.1007\/s00277-025-06701-7"},{"key":"15939_CR19","doi-asserted-by":"publisher","first-page":"733364","DOI":"10.3389\/fimmu.2021.733364","volume":"12","author":"J Ye","year":"2021","unstructured":"Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol. 2021;12:733364.","journal-title":"Front Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15939-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:51:10Z","timestamp":1781646670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15939-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15939"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15939-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"641"}}